Immunotherapy: New insights in breast cancer treatment
- PMID: 33998534
- DOI: 10.3233/HAB-210443
Immunotherapy: New insights in breast cancer treatment
Abstract
Breast cancer being the most malignant and lethal disease persistent among women globally. Immunotherapy as a new treatment modality has emerged in understanding the loopholes in the treatment of breast cancer which is mainly attributed to the potential of tumor cells to evade and survive the immune response by developing various strategies. Therefore, improved understanding of the immune evasion by cancer cells and the monoclonal antibodies against PD- and PD-L1 can help us in the diagnosis of this malignancy. Here in this article, I have highlighted that in addition to focusing on other strategies for breast cancer treatment, the involvement of immune system in breast cancer is vital for the understanding of this malignancy. Further, the complete involvement of immune system in the relapse or recurrence of the breast tumor and have also highlighted the role of vaccines, PD-1 and CTLA-4 with the recent advances in the field. Moreover, in addition to the application of immunotherapy as a sole therapy, combinations of immunotherapy with various strategies like targeting it with MEK inhibitors, Vaccines, chemotherapy and PARP inhibitor has shown to have significant benefits is also discussed in this article.
Keywords: Breast cancer; CTLA-4; PARP inhibitor; PD-1; PD-L1; immunotherapy; vaccines.
Similar articles
-
Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.Clin Adv Hematol Oncol. 2016 Nov;14(11):922-933. Clin Adv Hematol Oncol. 2016. PMID: 27930644 Review.
-
Immune Checkpoint Blockade in Breast Cancer Therapy.Adv Exp Med Biol. 2017;1026:383-402. doi: 10.1007/978-981-10-6020-5_18. Adv Exp Med Biol. 2017. PMID: 29282694 Review.
-
The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.Eur J Pharmacol. 2021 Mar 15;895:173867. doi: 10.1016/j.ejphar.2021.173867. Epub 2021 Jan 15. Eur J Pharmacol. 2021. PMID: 33460617 Review.
-
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.Int Immunol. 2015 Jan;27(1):39-46. doi: 10.1093/intimm/dxu095. Epub 2014 Oct 16. Int Immunol. 2015. PMID: 25323844 Review.
-
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.Curr Oncol Rep. 2017 Aug 10;19(10):64. doi: 10.1007/s11912-017-0627-0. Curr Oncol Rep. 2017. PMID: 28799073 Review.
Cited by
-
Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity.Cancers (Basel). 2022 Jan 7;14(2):285. doi: 10.3390/cancers14020285. Cancers (Basel). 2022. PMID: 35053449 Free PMC article. Review.
-
Albumin-based nanosystem for dual-modality imaging-guided chem-phototherapy against immune-cold triple-negative breast cancer.Regen Biomater. 2023 Aug 31;10:rbad073. doi: 10.1093/rb/rbad073. eCollection 2023. Regen Biomater. 2023. PMID: 37799708 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials